Journal List > J Korean Soc Transplant > v.25(1) > 1034360

J Korean Soc Transplant. 2011 Mar;25(1):8-14. Korean.
Published online March 31, 2011.
Copyright © 2011 The Korean Society for Transplantation
Management of Posttransplantation Diabetes Mellitus (PTDM)
Bong Soo Cha, M.D., and Jae Hoon Moon, M.D.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author (Email: )
Received February 28, 2011; Accepted March 03, 2011.


New-onset diabetes after transplantation (NODAT) is a common complication of solid-organ transplantation. As long-term posttransplant survival continues to improve, increasing attention has been placed on NODAT. Because NODAT is a potent predictor of graft failure and cardiovascular mortality in the transplant population, early detection and management of NODAT are important issues. The risk factors for NODAT in transplant recipients include older age, obesity, family history, hepatitis C virus infection, and immunosuppressive agents, such as corticosteroids and calcineurin inhibitors. Management of NODAT must be considered at the pretransplantation stage to screen high risk patients and prevent NODAT. Although NODAT management is similar to type 2 diabetes management in the general population, there are some specific considerations in NODAT management, including the immunosuppressive agent. Further studies are needed to suggest optimal management guidelines for NODAT.

Keywords: Diabetes mellitus; Organ transplantation; Risk factors; Postoperative complications; Diagnosis; Treatment outcome


Table 1
Treatment guideline for type 2 diabetes patients
Click for larger image

1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178–185.
2. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10:349–355.
3. Benhamou PY, Penfornis A. Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab 2002;28:166–175.
4. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979–983.
5. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976;271:202–210.
6. Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;34:1–13.
7. Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrøm J, Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001;16:829–835.
8. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991;51:374–377.
9. Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997;8:294–301.
10. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583–595.
11. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, van Veldhuisen P. Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564–577.
Erratum in: Am J Transplant 2008;8:1080.
12. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307–316.
13. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, et al. CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807–814.
14. Yagisawa T, Takahashi K, Teraoka S, Toma H, Agishi T, Ota K. Effects of cyclosporine on glucose metabolism in kidney transplant recipients and rats. Transplant Proc 1987;19:1801–1803.
15. Hahn HJ, Dunger A, Laube F, Besch W, Radloff E, Kauert C, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986;29:489–494.
16. Garvin PJ, Niehoff M, Staggenborg J. Cyclosporine's effect on canine pancreatic endocrine function. Transplantation 1988;45:1027–1031.
17. Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc 1988;20 3 Suppl 3:985–988.
18. Strasser S, Alejandro R, Shapiro ET, Ricordi C, Todo S, Mintz DH. Effect of FK506 on insulin secretion in normal dogs. Metabolism 1992;41:64–67.
19. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995;59:1606–1613.
20. van Hooff JP, van Duijnhoven EM, Christiaans MH. Tacrolimus and glucose metabolism. Transplant Proc 1999;31:49S–50S.
21. Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72:1655–1661.
22. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590–598.
23. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506–1514.
Erratum in: Am J Transplant 2008;8:1. Am J Transplant 2008;8:908. Dosage error in article text.
24. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423–428.
25. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón del Prado JM, Pulpón LA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 2006;6:1387–1397.
26. Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Friedman EA, et al. Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors. Transplantation 1991;51:343–347.
27. Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;72:1020–1024.
28. Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002;17:1–5.
29. Neylan JF. FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998;65:515–523.
30. Williams JJ, Lund LH, LaManca J, Kunavarapu C, Cohen DJ, Heshka S, et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant 2006;25:36–41.
31. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005;5:2710–2718.
32. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732–737.
33. Marrero D, Hernandez D, Tamajón LP, Rivero M, Lampreabe I, Checa MD, et al. For the Spanish Late Allograft Dysfunction Study Group. Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multi-centre cohort Spanish study. NDT Plus 2010;3 Suppl 2:ii15–ii20.
34. Grimbert S, Valensi P, Lévy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996;20:544–548.
35. Gürsoy M, Güvener N, Köksal R, Karavelioğlu D, Baysal C, Ozdemir N, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000;32:561–562.
36. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374–1380.
37. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066–1072.
38. Konrad T, Vicini P, Zeuzem S, Toffolo G, Briem D, Lormann J, et al. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999;107:343–349.
39. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003;14:2092–2098.
40. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739–744.
41. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005;5:2433–2440.
42. Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550–1556.
43. Hjelmesaeth J, Müller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005;20:2311–2315.
44. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291–298.
45. Joss N, Staatz CE, Thomson AH, Jardine AG. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007;21:136–143.
46. Iida S, Ishida H, Tokumoto T, Omoto K, Shirakawa H, Shimizu T, et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT. Int Urol Nephrol 2010;42:935–945.
47. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001;1 Suppl 2:3–95.
48. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. International Expert Panel. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75 10 Suppl:SS3–SS24.
49. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5–S20.
50. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management-2000 update. Endocr Pract 2000;6:43–84.
51. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008;85:353–358.
52. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111–119.
53. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388–399.
54. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005;80:1402–1405.
55. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135–2138.
56. Säemann MD, Krebs M. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? Wien Klin Wochenschr 2010;122:198–202.
57. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007;47:165–174.
58. American Diabetes Association. Summary of revisions to the 2011 clinical practice recommendations. Diabetes Care 2011;34 Suppl 1:S3.